期刊文献+

普罗布考及其衍生物防治动脉粥样硬化和血管成形术后再狭窄的研究现状及进展 被引量:4

Current Situation and Prospect in the Research of Probucol and its Derivatives in Treating Atherosclerosis and Restenosis
下载PDF
导出
摘要 心脑血管疾病已成为中国居民首位死亡原因。作为冠心病和脑卒中的共同致病基础,动脉粥样硬化的发生是一个多因素引起的复杂病理过程。普罗布考以其独特的抗氧化、抗炎、降胆固醇及改善内皮功能等作用应用于临床治疗动脉粥样硬化和血管成形术后再狭窄已有多年。本文从普罗布考的作用机制、临床应用和其衍生物的开发利用等方面对普罗布考防治动脉粥样硬化和血管成形术后再狭窄的研究现状和进展做一综述。 Nowadays,cardio-cerebrovascular disease is a major cause of death in China. As a common pathogenic basis of coronary heart disease and stroke,atherosclerosis is a complex pathological process which is controlled by multiple factors. With its unique effects on anti-oxidation,anti-inflammation,cholesterol-lowering and improving endothelial function,probucol has been clinically used in preventing and treating atherosclerosis and coronary artery restenosis after angioplasty for decades. This review describes the situation and prospect in the research of probucol and its derivatives in treating atherosclerosis and restenosis from several aspects such as its mechanism,clinical application and the exploitation of its derivatives.
出处 《中国动脉硬化杂志》 CAS CSCD 北大核心 2014年第10期1062-1066,共5页 Chinese Journal of Arteriosclerosis
基金 国家重点基础研究发展计划973项目(2011CB503905)
关键词 普罗布考 动脉粥样硬化 胆固醇 炎症 氧化 Probucol Atherosclerosis Cholesterol Inflammation Oxidation
  • 相关文献

参考文献45

  • 1Yamamoto S, Tanigawa H, Li X, et al. Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice re- duces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport[J]. Circulation, 2011, 124(12): 1 382-390.
  • 2Zhong JK, Guo ZG, Li C, et al. Probucol alleviates atherosclerosis and improves high density lipoprotein function [ J ]. Lipids Health Dis, 2011, 10: 210.
  • 3Inagaki M, Nakagawa-Toyarna Y, Nishida M, et al. Effect of probu- col on antioxidant properties of HDL in patients with heterozygous fa- milial hypereholesterolemia [ J]. J Atheroscler Thromb, 2012, 19 (7) : 643-656.
  • 4Miida T, Seino U, Miyazaki O, et al. Prohucol markedly reduces HDL phospholipids and elevated prebetal-HDL without delayed con- version into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probneol-induced HDL remodeling[ J]. Atheroselerosis, 2008, 200(2) : 329-335.
  • 5Hong SC, Zhao SP, Wu ZH. Effect of probucol on HDL metabolism and class B type I scavenger receptor (SR-BI) expression in the liv- er of hypercholesterolemic rabbits [ J ]. lut J Cardiol, 2007, 115 ( 1 ) : 29-35.
  • 6倪占玲,王丽霞,赵水平.普罗布考对体内巨噬细胞胆固醇逆转运的作用[J].中国动脉硬化杂志,2013,21(8):695-699. 被引量:4
  • 7Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome[ J]. N Engl J Med, 2012, 367(22) : 2 089-099.
  • 8Mora S, Glynn R J, Ridker PM. High-density lipoprotein cholester- ol, size, particle number, and residual vascular risk after potent sta- tin therapy[ J ]. Circulation, 2013, 128 ( 11 ) : 1 189-197.
  • 9Wu B J, Kathir K, Witting PK, et al. Antioxidants protect from ath- erosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging [ J ]. J Exp Med, 2006, 203 (4) : 1 117-127.
  • 10Choy K, Beck K, Prig FY, et al. Processes involved in the site- specific effect of probucol on atherosclerosis in apolipoprotein E gene knockout mice[ J]. Arterioscler Thromb Vasc Biol, 2005, 25 (8) : 1 684-690.

二级参考文献58

  • 1王远程,叶志斌,周钦,张宗梁,吴兆龙.丙丁酚抑制氧化型低密度脂蛋白诱导系膜细胞转化生长因子-β_1表达[J].复旦学报(医学版),2005,32(2):151-154. 被引量:9
  • 2范利,朱冰坡,曹剑,李小鹰,曾强.普罗布考对老年下肢动脉硬化症患者血管内皮活性因子及炎性因子的影响[J].微循环学杂志,2006,16(3):55-57. 被引量:5
  • 3中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5223
  • 4Albelda SM, Oliver PD, Romer LH, et al. Endocam : a novel endothelial cell-cell adhesion molecule [ J ]. J Cell Biol, 1990, ll0(d): 1 227-237.
  • 5Muller WA, Berman ME, Newman PJ, et al. A heterophilic adhesion mechanism for platelet/endothelial cell adhesion molecule I(CD31) [J]. J Exp Med, 1992, 175(5): 1 401-404.
  • 6Sawayama Y, Shimizu C, Maeda N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST) [ J ]. J Am Coil Cardiol, 2002, 39 (4): 610-616.
  • 7Tanous D, Hime N, Stocker R. Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds [J]. Redox Pep, 2008, 13(2): 48-59.
  • 8Iqbal M, Okazaki Y, Okada S, et al. Probueol modulates iron nitrilotriacetate (Fe·NTA) -dependent renal carcinogenesis and hyperprolifemtive response: diminution of oxidative stress[J]. Mol Cell Biochem, 2007, 304 : 61-69.
  • 9Yoshikawa T, Mitani K, Kotosai K, et al. Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet[J]. Horm Metab Res, 2008, 40: 473-478.
  • 10Brownlee M. The pathobiology of diabetic complications, a unifying mechanism[J]. Diabetes, 2005, 54:1 615- 618.

共引文献24

同被引文献28

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部